KR20200088074A - Skin external composition comprising centella asiatica extract and papaver rhoeas extract - Google Patents

Abstract

The present invention relates to a composition for external application for skin comprising a natural material. More particularly, the present invention provides a cosmetic and pharmaceutical composition which is excellent in skin soothing effect, skin moisturizing effect, anti-inflammatory effect and anti-allergic effect by containing a mixed extract of Centella asiatica extract and Papaver rhoeas extract as an active ingredient, and thus can be usefully used for the prevention, amelioration and treatment of skin diseases.

Description

Composition for external application for skin comprising Centella extract and poppy extract {SKIN EXTERNAL COMPOSITION COMPRISING CENTELLA ASIATICA EXTRACT AND PAPAVER RHOEAS EXTRACT}

The present invention relates to a composition for external application for skin comprising a natural material, and more specifically, it contains a mixed extract containing an extract of coleoptera and a poppy extract as an active ingredient, and is useful for skin soothing, skin moisturizing, anti-inflammatory or anti-allergic. It relates to cosmetic and pharmaceutical compositions that can.

Skin is divided into three layers of epidermal, dermal and subcutaneous fat tissue in order from the outside, and is a tissue that covers the outside of the body. It is a variety of physiological that protects the body from environmental factors such as various external stimuli, obstacles, and dryness. It functions to protect and regulate internal organs and other organs in the body.

Irritation to the skin may include environmental factors such as sunlight, wind, cold and dry air, infections, shaving scratches, repetitive or excessive washing or bathing, mechanical scratches or damage, and physical and chemical factors and sensitivity or It may also depend on genetic factors.

In order to prevent skin damage caused by skin irritation and skin aging caused by internal and external factors, to maintain a healthier and more beautiful skin, physiologically active substances obtained from various animals, plants, and microorganisms are added to external skin preparations such as cosmetics. Efforts to maintain skin health by promoting skin metabolism by maintaining the intrinsic function of the skin and activating skin cells by use have been conducted, and various studies have been conducted accordingly.

Centella asiatica is a perennial crawling medicinal plant mainly found in South Asia, and inhabits lowland wetlands in Jeju Island and in the central and southern regions of Korea. The main components of the bottled grass are madecassoside, madecassic acid, asiaticoside, and asiatic acid. These ingredients have been used for the treatment of skin wounds, chronic ulcers, etc., and have good antibacterial properties and have been reported to be effective in skin diseases and antirheumatic arthritis. In addition, the effects of promoting the cell cycle of skin cells, promoting proliferation and collagen synthesis, and inhibiting skin aging have been reported (Park Ji-eun, 2010), and studies to utilize them are actively being conducted.

As a related prior art, Korean Patent Publication No. 10-2017-0103172 utilizes a moisturizing effect based on strengthening the skin barrier of ceramide and maintaining the moist skin due to the control of moisturizing factors to extract the bottled extract, ceramide and birch sap. A cosmetic composition for alleviating skin irritation and improving skin barrier is disclosed, and Korean Patent Publication No. 10-2015-0045049 discloses a liquid extract of cypress leaf, a liquid extract of pine needles, a liquid extract of pine needles, a liquid extract of pine needles and green tea leaves A cosmetic composition for moisturizing skin containing a fermented extract obtained after fermenting a liquid extract and an alkaline ionized water as an active ingredient and a method for manufacturing the same are disclosed. Disclosed is a synergistic antimicrobial and skin protection composition for moisturizing skin comprising at a rate of 0.3 to 3.

As described above, it is already known that by using the extract of Centella in the skin, there is a wound healing effect. However, there has been no known research on the poppy extract or by using the extract of the medicinal herb with the extract of the poppy, synergistically increasing the effectiveness of the extract.

Korean Patent Publication No. 10-2017-0103172 Korean Patent Publication No. 10-2015-0045049 Korean Patent Publication No. 10-2007-0111785

The present invention is to solve the problems as described above, by containing a mixed extract containing an extract of yeokpoe and poppy extract as an active ingredient, skin soothing, skin moisturizing, anti-inflammatory or anti-allergic useful cosmetic and pharmaceutical It is an object to provide a composition.

According to one aspect of the present invention, there is provided a cosmetic composition characterized in that it contains a mixed extract comprising a centella extract and a poppy extract.

The mixed extract may provide a cosmetic composition characterized by comprising a centella extract and a poppy extract in a weight ratio of 1: 0.2 to 1: 10.

The mixed extract may provide a cosmetic composition characterized in that it contains 0.001 to 50% by weight relative to the total weight of the cosmetic composition.

The cosmetic composition may provide a cosmetic composition characterized in that it is for skin soothing, skin moisturizing, anti-inflammatory or anti-allergic.

According to another aspect of the present invention, there is provided a pharmaceutical composition for soothing skin containing a mixed extract comprising an extract of coleoptera and a poppy extract as an active ingredient.

According to another aspect of the present invention, there is provided a quasi-drug composition for skin soothing, containing a mixed extract comprising a centella extract and a poppy extract as an active ingredient.

According to the cosmetic composition and pharmaceutical composition containing the mixed extract containing the extract of medicinal herb extract and poppy extract according to the present invention as an active ingredient, it is excellent in skin soothing effect, skin moisturizing effect, anti-inflammatory effect and anti-allergic effect, preventing skin disease, It can be usefully used for improvement and treatment.

Hereinafter, embodiments of the present invention will be described in detail. However, this is provided as an example, and the present invention is not limited thereby, and the present invention is only defined by the scope of claims to be described later.

In describing the present invention, when it is determined that detailed descriptions of related known configurations or functions may obscure the subject matter of the present invention, detailed descriptions thereof will be omitted.

In describing the components of the present invention, terms such as first, second, A, B, (a), and (b) may be used. These terms are only for distinguishing the component from other components, and the nature, order, or order of the component is not limited by the term.

In describing the present invention, the terms'about','substantially','degree', etc. of degree are used in or close to the value when manufacturing and substance tolerances unique to the stated meaning are presented. In order to aid the understanding of the present invention, accurate or absolute values are used to prevent unconscionable infringers from using the disclosed disclosure.

In the present invention, the extract is obtained by immersing the desired substance in various solvents, and then extracting liquid components obtained by extracting for a period of time at room temperature, low temperature, or heating, and solids obtained by removing the solvent from the liquid components. it means. In addition, in addition to the above results, it can be comprehensively interpreted as including all of the dilutions of the above results, their concentrates, their fractions, coordinating agents, and purified products.

In the present invention, the terms'prevention','improvement' or'treatment' means suppression, alleviation or elimination of the appearance or development of one or more symptoms associated with a disease or disorder.

In the present invention, the term'skin external preparation' is a concept encompassing the overall composition applied to the skin, for example, various cosmetics such as basic cosmetics, makeup cosmetics, hair cosmetics, skin care products, ointments, creams, lotions It is a concept that includes pharmaceutical compositions for topical administration including pharmaceutical products such as drugs and quasi-drugs.

The external preparation for skin according to an embodiment of the present invention may contain a mixed extract comprising a centella extract and a poppy extract.

In the present invention, Centella asiatica is a perennial plant belonging to the apiaceae family that blooms white or light purple flowers on small fan-shaped leaves with serrated edges. Since it grows in warm and humid areas, it is commonly found in the mountains and fields of the southern islands such as Jeju Island in Korea. In India, wounded tigers have been used as a medicine for a long time because they were called tiger tigers because they saw a wounded tiger healed in a lot of diseased grass.

Madecassoside, madecassic acid, asiaticoside, and asiatic acid are known as the main active ingredients of coriander. Asiatic acid has been known to have anti-cancer effects in various carcinomas, and Asiaticoside or its derivatives are known to be effective for skin ulcers, extensive trauma treatment, skin veins, vein ulcers, erosive skin ulcers, and alopecia areata . Madekasic acid on the leaves and stems of Cypress has been known to help heal inflammation and heal wounds such as tumors and ulcers. Cypress extract promotes collagen synthesis to promote skin elasticity and wound healing. It is excellent in improving acne and atopy, and is known to have skin rejuvenation effect and pore shrinking effect with collagen ingredients.

In the present invention, poppy poppy (Papaver rhoeas) Is called Umiincho (·美人草)·baby baby opium flower and is a biennial plant of the poppy family. Flowers are usually red, but have different colors depending on varieties, and bloom in May-June, and hang one at the end of branches. Before the flowers bloom, the buds face downwards, but when they bloom, they face upwards. Calyx leaves are 2, green, edge white, hairy on the outside. The petals are 4, alternating, slightly rounded, and have a number of stamens, the ovaries are obovate, hairless, and the radial and fruit are broad obovate, with saxes. It is known that the flowers, ground, and outposts of poppy flowers have effects such as soothing, hypnosis, and analgesic effects.

Poppy family, which belongs to the poppy family, has various phytochemicals such as alkaloids, anthocyanins, and phenolic compounds. It has major phytochemical components such as rhoeagenine, anthocyanin (cyanidine, mecocyanin), berberine, and protoberberine. Although the main phytochemical component is known to have anti-oxidation, antibacterial, anti-inflammatory, anti-fibrosis, and skin-protecting effects, it is expected to have high utilization, but until now, medicinal or cosmetic research on poppy has not been active. Moreover, its utilization is not high.

In the present invention, it was confirmed that the extract of the poppy poppy further increases the synergistic effect by using mixed with other plant extracts.

That is, although it has already been known that there is an effect of wound healing on the skin of the extract, the present inventors use skin extract, and extract of poppy extract together, soothing the skin, moisturizing, anti-inflammatory or anti-inflammation of the skin. It has been found that the allergic effect is synergistically superior, and further, such a synergistic effect can be further increased by adjusting the blending ratio.

In the present invention, the hyacinth extract and the poppy extract can be extracted from various organs of natural, hybrid, and varietal plants.

In the present invention, the medicinal herb extract is extractable from plant tissue cultures, as well as the outpost, root, terrestrial, stem, leaf, flower, fruit body, and peel of the fruit.

In the present invention, the poppy extract is extractable from the plant tissue culture as well as the outpost, root, ground, stem, leaves, flowers, the trunk of the fruit, and the peel of the fruit.

The method of extraction or the type of the solvent for obtaining the extract is not particularly limited. As the solvent, alcohols such as ethanol, methanol, propanol, glycerin and propylene glycol, water, organic solvents such as ether, acetone, ethyl acetate, chloroform, and hexane, or a combination of these can be used. However, from the viewpoint of safety, it is preferable to extract using water, ethanol, or a mixed solution thereof.

The method for obtaining the extract is not particularly limited, and specifically, dipping in the above solvent, immersing the bottled grass, the outpost of the poppy, the root, the stem, the leaves, the fruit, the flowers, their dried products, and the like, at room temperature. Methods such as a cold immersion extraction method, a heating extraction method, an ultrasonic extraction method by applying ultrasonic waves, and a reflux extraction method using a reflux cooler can be used.

In the present invention, the mixed extract may be an extract obtained by mixing the extracts of each component of Centella, Poppy, in an appropriate weight mixing ratio, and may also be extracted after mixing Centella, Poppy, in an appropriate weight mixing ratio. It was confirmed that the mixed extract was more effective for skin soothing, skin moisturizing, anti-inflammatory, or anti-allergic than the single extract of each medicinal herb, poppy, and it was found that it had an excellent synergistic effect.

The mixed extract may include a centella extract and a poppy extract in a weight ratio of 1: 0.2 to 1: 10, preferably 1: 0.5 to 1: 5, preferably 1: 1 to 1: 3. If the weight ratio of the poppy extract compared to the centella extract is less than 0.2, the efficacy is not sufficiently exhibited, and if it exceeds 10, there is a problem that the effect is decreased.

It is also possible to use the extract in the form of a solution, but after further filtering and distilling off the extraction solvent, it can be used in powder form by drying under reduced pressure or freeze drying, or concentrated. Moreover, it is also possible to use those obtained by fractional purification by organic solvent fractionation, column chromatography, or the like. In addition, purification treatment such as deodorization and decolorization may be added.

In the present invention, the active ingredient of the mixed composition is 0.001 to 50% by weight, preferably 0.01 to 50% by weight, preferably 0.01 to 20% by weight, preferably 0.05 to 20% based on the total composition for external application for skin. Weight percent, preferably 0.1 to 20 weight percent, preferably 0.5 to 20 weight percent, preferably 0.5 to 10 weight percent. If the weight of the mixed composition is less than 0.001% by weight, efficacy and effectiveness may be insignificant, and if it exceeds 50% by weight, there may be skin stability or formulation problems.

According to an embodiment of the present invention, the external preparation for skin containing a mixed extract comprising a centella extract and a poppy extract may be a cosmetic composition.

In the present invention, the cosmetic composition has a skin soothing, skin moisturizing, anti-inflammatory or anti-allergic effect by containing the mixed composition as an active ingredient.

In the present invention, the skin soothing, if the skin cells are damaged by internal or external stimulation, such as skin reddened or sensitive skin due to sunlight or ultraviolet rays, skin sensitive to congenital sensitive skin or irritation, or alleviate it. Recovery refers to, but is not particularly limited to.

In the present invention, the skin moisturizing refers to inhibiting moisture loss and strengthening of the skin barrier and the efficacy of supplying moisture to the skin so that the skin does not disappear quickly and stays on the skin for a long time.

In the present invention, the anti-inflammatory means a kind of defense mechanism, which means to resist inflammation, and the inflammation is caused by the signaling system of the immune response system, specifically atopic dermatitis, allergic dermatitis, inflammatory skin disease, immunity Diseases and asthma, but are not necessarily limited to this.

In the present invention, the anti-allergic is meant to include improvement, treatment of allergic diseases, prevention of such diseases (inhibition or delay of onset), and the allergic diseases are allergic mediated activation of mast cells, such as degranulation of mast cells. Refers to pathological symptoms caused by reactions.Atopic dermatitis, allergic asthma, allergic rhinitis, allergic conjunctivitis, and allergic dermatitis allergic dermatitis), allergic contact dermatitis, allergic keratitis, and the like, but are not particularly limited thereto.

The cosmetic composition is softening lotion, nutrient makeup, moisture cream, nutrition cream, massage cream, nutrition lotion, essence, ampoule, gel, eye cream, oil, foundation, cleansing cream, cleansing foam, cleansing water, shampoo, rinse, pack, It may be formulated with one or more selected from the group consisting of sprays and powders.

Specifically, the cosmetic composition may be prepared as a general emulsifying formulation and a solubilizing formulation. For example, lotion such as soft lotion or nutrition lotion, emulsion such as facial lotion, body lotion, nutrition cream, moisture cream, cream such as eye cream, essence, cosmetic ointment, spray, gel, pack, sunscreen, makeup base, liquid It may be formulated as a type, solid type or spray type foundation, powder, cleansing cream, cleansing lotion, makeup remover such as cleansing oil, or a cleansing agent such as cleansing foam, soap, and body wash, but is not limited thereto.

The cosmetic composition may be appropriately blended with other ingredients within a range that does not impair the purpose according to the present invention depending on the type of formulation or purpose of use in addition to the essential ingredients in each formulation.

The cosmetic composition may include an acceptable carrier, for example, oil, water, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, fragrances, etc. can be appropriately blended. no.

The permissible carrier may vary depending on the formulation of the cosmetic composition.

For example, when formulated as ointments, pastes, creams or gels, animal oils, vegetable oils, waxes, paraffins, starches, tracants, cellulose derivatives, polyethylene glycols, silicones, bentonite, silica, talc, zinc oxide or Mixtures of these may be used, but are not limited thereto.

When the cosmetic composition is formulated as a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or a mixture thereof may be used as a carrier component, and in the case of a spray, chlorofluorohydro Carbon, propane, butane or dimethyl ether may further include a propellant, but is not limited thereto.

When the cosmetic composition is formulated as a solution or an emulsion, a solvent, a solubilizing agent, or an emulsifying agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, and propylene glycol , Butylene glycol oil can be used, in particular, cottonseed oil, peanut oil, corn seed oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan may be used, but is not limited thereto. It does not work.

When the cosmetic composition is formulated as a suspension, a liquid diluent such as water, ethanol or propylene glycol as a carrier component, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester , Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or trakant, and the like, but are not limited thereto.

When the cosmetic composition is formulated with soap, alkali metal salt of fatty acid, fatty acid hemiester salt, fatty acid protein hydrolyzate, isethionate, lanolin derivative, aliphatic alcohol, vegetable oil, glycerol, sugar, etc. It can be used, but is not limited thereto.

When the cosmetic composition is formulated into a pack, a peel-off pack containing polyvinyl alcohol or the like, wash-off containing pigments such as kaolin, talc, zinc oxide, or titanium dioxide in a general emulsifying cosmetic. It includes all forms of a pack or a mask sheet pack, but is not limited thereto.

The cosmetic composition according to the quality or function of the final product, fatty substances, organic solvents, solubilizers, thickening agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances commonly used in the industry , Surfactant, water, ionic or nonionic emulsifier, filler, metal ion blocker, chelating agent, preservative, blocking agent, wetting agent, essential oil, dye, pigment, hydrophilic or lipophilic active agent, commonly used in cosmetics It may further contain adjuvants commonly used in the cosmetic or dermatological field, such as any other ingredient.

According to an embodiment of the present invention, the external preparation for skin containing a mixed extract comprising a centella extract and a poppy extract may be a pharmaceutical composition available for skin soothing, skin moisturizing, anti-inflammatory or anti-allergic.

The pharmaceutical composition may further include a pharmaceutically acceptable carrier.

In the present invention, the term'pharmaceutically acceptable carrier' refers to a carrier or diluent that does not stimulate the organism and does not inhibit the prophylactic or therapeutic activity and properties of the pharmaceutical composition according to the present invention. As a pharmaceutical carrier acceptable in a composition formulated as a liquid solution, as a sterile and biocompatible material, saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol And one or more of these components may be used in combination, and other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added as necessary.

In addition, the pharmaceutically acceptable carrier may include a non-naturally occurring carrier.

The pharmaceutical composition may be administered in single or multiple amounts in a pharmaceutically effective amount.

In the present invention, the term'pharmaceutically effective amount' refers to an amount sufficient to prevent or treat a disease at a ratio of reasonable benefit/risk applicable to medical prevention or treatment, and the effective dose level is the severity of the disease, the drug The activity, patient's weight, health, sex, patient's sensitivity to the drug, the time of administration of the composition of the present application used, the route of administration and release rate, the duration of treatment, the drug used in combination with or concurrently with the composition of the present application used. It may be determined by factors including and other factors well known in the medical field.

According to an embodiment of the present invention, the external preparation for skin containing a mixed extract comprising a centella extract and a poppy extract may be a quasi-drug composition that can be used for skin soothing, skin moisturizing, anti-inflammatory, or anti-allergic.

In the present invention, the term'quasi-drug' refers to articles with less action than pharmaceuticals among articles used for the purpose of diagnosing, treating, improving, alleviating, treating or preventing diseases of humans or animals, for example, the Korean Pharmaceutical Affairs Law According to the article, quasi-drug products exclude products used for pharmaceutical use, and include products used to treat or prevent disease in humans and animals, and products that have little or no direct action on the human body.

The quasi-drug composition may be prepared in a form selected from the group consisting of body cleanser, foam, soap, mask, ointment, cream, lotion, essence and spray, but is not limited thereto.

When using a mixed extract comprising a centella extract and a poppy extract according to the present invention as quasi-drug additives, the mixed extract can be added as it is or used with other quasi-drugs or quasi-drug components, and can be suitably used according to conventional methods. The mixing amount of the active ingredient can be appropriately determined according to the purpose of use.

Hereinafter, the present invention will be further described through production examples and test examples. These examples are intended to illustrate the present invention more specifically, but the scope of the present invention is not limited to these examples.

[ Example ]

[ Manufacturing example ]

[Production Example 1] Preparation of extract

1. Preparation of Centella extract

The top portion of the bottle pool was washed with distilled water, dried at 50°C, and then pulverized to a powder. 1 L of 70% (w/v) ethanol was added to 100 g of Centella powder, extracted by immersion at room temperature for about 3 hours, and after filtering the obtained extract, the filtrate was concentrated under vacuum under reduced pressure to obtain 4.5 g of Centella extract.

2-1. Preparation of ground poppy extract

The ground portion of the blooming poppy was washed clean with distilled water, dried at 50° C., and pulverized to a powder. 1 L of 70% (w/v) ethanol was added to 100 g of ground poppy powder, immersed for 3 hours at room temperature, and the obtained extract was filtered, and the filtrate was concentrated under vacuum under reduced pressure to obtain 3.9 g of ground poppy extract. .

2-2. Preparation of Gaeyang poppy flower extract

The poppy flowers were washed clean with distilled water, dried at 50° C., and then pulverized to a powder. 1 g of 80% (w/v) ethanol was added to 100 g of poppy flower powder, immersed for 3 hours at room temperature, and the obtained extract was filtered, and the filtrate was concentrated under reduced pressure in vacuum to obtain 3.5 g of poppy flower extract. .

3. Preparation of aloe extract

The aloe was washed with distilled water, dried, pulverized with a blender, and powdered, and a solvent mixed with purified water and ethanol in a 5:5 ratio was added in a volume of about 10 times, followed by extraction twice. After performing the extraction, filtered through a 400 mesh filter cloth, and the obtained filtrate was concentrated using a vacuum concentrator to obtain an extract powder.

[Production Example 2] Preparation of the composition

Compositions according to Examples and Comparative Examples were prepared with the compositions shown in Table 1 below using the screen extracts prepared by Preparation Example 1, ground extracts of poppy poppy, extracts of poppy poppy and aloe extract.

Centella extract Poppy field
extract Poppy flower extract Aloe extract Untreated - - - - Comparative Example 1 One - - - Comparative Example 2 - One - - Comparative Example 3 One - - One Example 1 One 0.2 - - Example 2 One - 0.5 - Example 3 One One - - Example 4 One - 2 - Example 5 One 3 - - Example 6 One 5 - - Example 7 One 10 - - Weight ratio

[Production Example 3] Preparation of cosmetics

As shown in Table 2, toner, ampoule, lotion and the like containing the composition of the present invention as an active ingredient were prepared according to a conventional cosmetic manufacturing method.

ingredient Example 8
(toner) Example 9
(ample) Example 10
(Lotion) Example 1 1.00 Example 3 1.50 Example 4 2.00 Carbomer 0.20 0.40 0.60 Dipropylene glycol 8.00 10.00 4.00 Butylene Glycol 2.00 2.00 4.00 glycerin 2.00 5.00 4.00 Trehalose 0.50 1.00 0.10 Betaine 0.50 0.50 0.10 Sodium hyaluronate 0.01 0.02 - Xanthan gum - - 0.05 Ethylhexyl palmitate - - 4.00 Cyclopentasiloxane - - 3.00 Seteares-30 - - 3.00 Cetyl alcohol - - 3.00 Hydrogenated poly(C-14 olefin) - - 3.00 Sodium stearoyl glutamate - - 0.50 1,2-hexanediol 1.00 1.00 1.00 ethanol 1.00 - - PG-40 Hydrogenated Castor Oil 0.25 0.40 - Hydrolyzed jojoba ester 0.10 - - Spices 0.02 0.05 0.04 Arginine 0.20 0.40 0.60 Ethylhexylglycerin 0.15 0.15 0.15 Caprylyl glycol 0.15 0.15 0.15 Purified water Up to 100 Up to 100 Up to 100 Unit: weight%

[ Test example ]

[Test Example 1] Skin keratinocytes culture

The skin keratinocytes, HaCaT cells, were 37°C, 5% CO ₂ incubator using Dulbecco's Modified Eagle's Medium (DMEM) medium containing 100 units/ml penicillin-streptomycin and 10% fetal bovine serum (FBS) from CG Hyun (Jeju National University, Korea) Cultured at 3-4 days intervals.

[Test Example 2] Cytotoxicity evaluation (EZ-cytox assay)

The EZ-cytox assay is a representative method of measuring cell viability using the principle that water solution tetrazolium salt (WST) reacts with dehydrogenase of living cells to produce orange water-soluble formazan.

To check the toxicity in keratinocytes, HaCaT cells were dispensed into 96 well plates at 5 X 10 ⁴ cells/mL using DMEM medium with 10% FBS added for 18 hours at 37°C and 5% CO ₂ conditions. Cultured for a while. The cultured HaCaT cells were exchanged with serum-free DMEM to treat the composition to be evaluated. Thereafter, EZ-cytox was added to each well and reacted at 37°C and 5% CO ₂ for 30 minutes, and absorbance at 450 nm was measured using a microplate reader. The average absorbance value for each sample group was determined, and the cell viability was evaluated by comparing with the absorbance value of the control group.

division Treatment concentration (μg/mL) Cytotoxic HaCaT cell viability (%) Untreated - 100 Comparative Example 1 100 103 ± 2.1 Comparative Example 2 100 101 ± 1.2 Comparative Example 3 100 103 ± 1.3 Example 1 100 101 ± 4.1 Example 2 100 105 ± 3.2 Example 3 100 104 ± 1.1 Example 4 100 105 ± 3.2 Example 5 100 101 ± 4.1 Example 6 100 104 ± 1.1 Example 7 100 101 ± 4.1

Looking at Table 3, in Comparative Examples 1 to 3 and Examples 1 to 7, which are compositions according to the present invention, cytotoxicity was not observed.

[Test Example 3] Skin soothing (skin irritation) effect

The human fibroblast cell line (ATCC, Cat. No. CRL-2076) was mixed at a density of 1 X 10 ⁵ cells/mL, and a collagen solution containing 200 µl of fibroblasts was added to an insert having a diameter of 10 mm to prepare the dermis. . After the dermis was prepared, DMEM containing 10% FBS was replaced every 2 days and cultured for 7 days. After 10 µl of the skin irritant SLS (sodium lauryl sulfate) was administered on the cultured dermis, 10 µl of the composition prepared according to Table 1 was applied 4 hours later, and then cultured at 37° C., 5% CO ₂ for 24 hours. DMSO was used as the solvent of the SLS and extract, and the concentration was set as the weight percentage of toxic substances to the solution. IL-1α was taken from a medium sample and used in the Human IL-1α assay kit (Endogen Inc. Boston, MA, USA), and measured at 450 nm with an ELISA-reader (enzyme-linked immunosorbent assay).

division Treatment concentration (μg/mL) IL-1α release (pg/mL) Untreated group (SLS) - 92.1 Comparative Example 1 100 90.5 Comparative Example 2 100 85.3 Comparative Example 3 100 79.1 Example 1 100 60.8 Example 2 100 56.1 Example 3 100 50.3 Example 4 100 52.2 Example 5 100 58.4 Example 6 100 67.2 Example 7 100 70.4

Looking at Table 4, it can be seen that the treatment of Examples 1 to 7, which is the composition according to the present invention, is higher than that of Comparative Examples 1 to 3, thereby inhibiting the production of IL-1α, thereby having a higher relieving effect on skin irritation.

[Test Example 4] Anti-allergic experiment (β-hexosaminidase release measurement)

β-hexosaminidase (β-hexosaminidase) is an enzyme contained in mast cells. When mast cells are activated by an immune response, they are released together with histamine. Therefore, β-hexosaminidase can be used as an indicator of degranulation of mast cells (Planta Med. 64, 577-578 (1998)).

RBL-2H3 cells were cultured by dispensing into 24 well plates at 5 X 10 ⁵ cells/mL using EMEM (Eagle's Minimum Essential Medium) medium containing 10% FBS and glutamine. As the medium used at this time, 0.5 μg/ml of mouse monoclonal immunoglobulin E (mouse monoclonal IgE) was used in the EMEM medium, and cultured in a 37° C., 5% CO ₂ incubator for 24 hours.

Cells were rinsed with 500 µl per well of siraganian buffer I (containing pH 7.2, sodium chloride 119 mM, potassium chloride 5 mM, magnesium chloride 0.4 mM, PIPES 25 mM and sodium hydroxide 40 mM) After adding 160 μl of Nian Buffer II (5.6 mM glucose, 1 mM potassium chloride and 0.1% BSA), the cells were incubated for 10 minutes in a 37° C., 5% CO ₂ incubator. After treatment with the composition prepared according to Table 1, incubated for 20 minutes in a 37°C, 5% CO ₂ incubator, and treated with antigen (1 μg/ml, DNP-BSA) for 10 minutes. The reaction was stopped by an ice bath for about 10 minutes and centrifugation was performed. After treating 20 μl of the substrate (1 mM ρ-nitrophenyl-N-acetyl-β-D-glucosaminid) in the supernatant, incubate for 1 hour at 37° C., 5% CO ₂ incubator, and 0.1M Na ₂ CO ₃ / The reaction was stopped by adding NaHCO ₃ . Absorbance at 405 nm was measured using an ELISA reader, and the inhibition rate was calculated as follows, and the results are shown in Table 4.

※ Inhibition rate (%) = {1-(B-C-D)/(A-C-D)}×100

A (control): No test substance added (antigen IgE response measurement)

B (treatment group): Test substance added (antigen IgE reaction measurement)

C(blank): Test substance and substrate added to ELISA plate

D (No treatment group): Antigen, IgE and test substance not added

division Treatment concentration (μg/mL) Inhibition rate (%) Comparative Example 1 100 21.3 Comparative Example 2 100 27.1 Comparative Example 3 100 15.3 Example 1 100 42.3 Example 2 100 45.5 Example 3 100 47.7 Example 4 100 51.3 Example 5 100 48.4 Example 6 100 46.2 Example 7 100 44.8

Looking at Table 5, it can be seen that the inhibition rate for allergies is higher when the Examples 1 to 7, which are the compositions according to the present invention, are treated than Comparative Examples 1 to 3.

[Test Example 5] Measurement of inflammation inhibition

To confirm the anti-inflammatory effect, an attempt was made to analyze the inhibitory activity of pro-inflammatory cytokines (IL-6: Interleukin-6, TNF-α: tumor necrosis factor-alpha).

RAW 264.7 cells were placed in a 48 well plate and attached for 18 hours. The composition prepared according to Table 1 and Lipopolysaccharide (LPS, 1 μg/mL) were treated together to incubate for a period of time. Thereafter, the culture medium was centrifuged (12,000 rpm, 3 min) to measure the proinflammatory cytokine production content of the supernatant. All samples were stored frozen (-20°C) until quantification. Pro-inflammatory cytokines were quantified using the mouse enzyme-linked immnunosorbent assay (ELISA ) kit (R & D Systems Inc., Minneapolis, MN, USA) r 2 value of the standard curve for the standard was at least 0.99.

sample Treatment concentration (μg/mL) Inhibition of TNF-α production (%) IL-6 inhibition (%) Comparative Example 1 100 21.4 ± 3.9 10.8 ± 1.8 Comparative Example 2 100 28.3 ± 1.8 48.1 ± 2.9 Comparative Example 3 100 37.1 ± 3.3 30.2 ± 2.1 Example 1 100 45.5 ± 1.2 56.7 ± 1.6 Example 2 100 48.8 ± 0.5 63.7 ± 1.7 Example 3 100 57.8 ± 2.3 68.7 ± 1.8 Example 4 100 69.4 ± 3.1 73.3 ± 3.0 Example 5 100 75.3 ± 2.8 70.3 ± 3.1 Example 6 100 71.3 ± 0.8 65.3 ± 3.0 Example 7 100 68.4 ± 3.1 58.3 ± 0.9 Dexamethason 10 65.2 ± 2.3 63.1 ± 2.2

Looking at the above Table 6, it can be seen that the treatment of Examples 1 to 7, which is the composition according to the present invention, is higher than that of Comparative Examples 1 to 3, which has a high inhibition rate of pro-inflammatory cytokine production.

[Test Example 6] Confirmation of the effect of increasing the production of hyaluronic acid (Hyaluronic Acid)

HaCaT cells were dispensed at 1.0 X 10 ⁵ cells/mL into 24 well plates and cultured for 18 hours at 37°C and 5% CO ₂ conditions. The cells were exchanged for Serum-free DMEM and cultured for 24 hours by treating the composition prepared according to Table 1 above. After that, the culture medium was collected, centrifuged at 15,000 rpm for 5 minutes, and the supernatant was taken out and stored frozen until quantification (-20°C). The enzyme immunoassay (ELISA: Enzyme-Linked Immunosorbent Assay) was used as a hyaluronic acid ELISA kit (Elabscience Biotechnology Co., Ltd) and was performed by the method provided by the manufacturer.

Treatment concentration (μg/mL) Hyaluronic Acid Production (%) Untreated - 100 Comparative Example 1 100 136 ± 2.8 Comparative Example 2 100 102 ± 2.1 Comparative Example 3 100 175 ± 5.6 Example 1 100 210 ± 5.9 Example 2 100 216 ± 1.7 Example 3 100 222 ± 2.2 Example 4 100 218 ± 6.1 Example 5 100 204 ± 3.3 Example 6 100 198 ± 2.2 Example 7 100 187 ± 2.2 Retinoic acid 10 243 ± 0.6

Looking at Table 7, it can be seen that when the Examples 1 to 7, which are the compositions according to the present invention, were treated, the amount of hyaluronic acid, a skin moisturizing factor, was higher than that of Comparative Examples 1 to 3.

[Test Example 7] Confirmation of the effect of increasing the amount of moisturizing factor Aquaporin3 (AQP3)

HaCaT cells were dispensed into 6 well plates at 4.0 X 10 ⁵ cells/mL and cultured at 37°C and 5% CO ² for 18 hours. The cells were exchanged for Serum-free DMEM and cultured for 24 hours by treating the composition prepared according to Table 1 above. Subsequently, each group was treated with PBS containing no drug that could affect protein quantification after removal of the culture solution and washing with PBS. It was lysed by repeating low temperature and room temperature incubation to collect proteins. Quantitatively, AQP3-ELISA kit (Elabscience Biotechnology Co., Ltd) was used and was performed by the method provided by the manufacturer.

Treatment concentration (μg/mL) Aquaporin3 production (%) Untreated - 100 Comparative Example 1 100 142 ± 5.4 Comparative Example 2 100 125 ± 4.8 Comparative Example 3 100 178 ± 4.3 Example 1 100 202 ± 4.8 Example 2 100 209 ± 2.6 Example 3 100 216 ± 4.2 Example 4 100 221 ± 6.2 Example 5 100 211 ± 4.2 Example 6 100 198 ± 2.9 Example 7 100 184 ± 4.8 Retinoic acid 10 234 ± 3.9

Looking at Table 8, it can be seen that in Comparative Examples 1 to 3, when the compositions 1 to 7 according to the present invention were treated, the amount of Aquaporin3, a skin moisturizing factor, was higher.

[Test Example 8] Measurement of skin moisture loss in damaged skin

The evaluation of transepidermal water loss under damaged skin was conducted on a total of 15 adults, 5 women in their 20s and 30s, and was measured using a Vapometer (Delfin Technologies Ltd, Finland). Tape stripping (hereinafter referred to as TS) to one anterior forearm (inner forearm) of the subjects induces skin damage, and in Examples 7 to 9 of Preparation Example 3 to a part (3 X 3 cm) of the TS-induced site. The test product prepared accordingly was applied, and the rest of the product was not applied. The measurement method for confirming the degree of improvement in the amount of skin epidermal moisture loss is repeated 3 times (10s/1 time) using a Vapometer 10 minutes after TS application, after TS application, and after product application. Measurement was performed and the average value was used as measurement data.

Product application area Product uncoated area TS Exhibition Before (after TS) Immediately after use TS Exhibition Before (after TS) Immediately after use Example 7
(toner) One 11.133 32 12.1 10.033 27.633 14.967 2 9.833 20.467 10.367 9.6 20.533 10.2 3 10 38.6 14.333 10.5 41.067 26.933 4 10.767 23.367 15.067 12.833 34.967 24.2 5 8.7 29.767 12.433 8.4 33.033 28.133 Average 10.0866 28.8402 12.8600 10.2732 31.4466 20.8866 Example 8
(ample) One 10.533 39.2 13.967 10.533 37.433 29.133 2 8.2 29.867 10.1 8.533 37.8 20.933 3 8.5 38.2 10.3 9.667 34.033 15.133 4 8.2 29.933 10.7 7.1 35.4 22.4 5 11.333 35.167 13.3 12.367 31.067 21.433 Average 9.3532 34.4734 11.6734 9.6400 35.1466 21.8064 Example 9
(Lotion) One 10.833 35.6 13.0335 10.283 32.533 22.05 2 9.0165 25.167 10.2335 9.0665 29.1665 15.5665 3 9.25 38.4 12.3165 10.0835 37.55 21.033 4 9.4835 26.65 12.8835 9.9665 35.1835 23.3 5 10.0165 32.467 12.8665 10.3835 32.05 24.783 Average 9.7199 31.6568 12.2667 9.9566 33.2966 21.3465

Looking at Table 9, it can be seen that the cosmetic composition containing bottled grass and poppies, which is a composition according to the present invention, has an excellent effect even when measuring the amount of transepidermal water loss under damaged skin. It was confirmed that the composition according to the present invention, which contains bottle grass and poppy, is excellent in skin soothing effect on damaged skin, as well as moisturizing and anti-inflammatory effect, and is very effective in use as a cosmetic and pharmaceutical composition.

The above description is merely illustrative of the present invention, and those skilled in the art to which the present invention pertains understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Will be able to. Therefore, the disclosed examples and experimental examples should be considered in terms of explanation, not limitation. The scope of the present invention is shown in the claims rather than the foregoing description, and all differences within the equivalent range should be interpreted as being included in the present invention.

Claims (6)

Cosmetic composition, characterized in that it contains a mixed extract comprising an extract of coleoptera and a poppy extract. According to claim 1,
The mixed extract is a cosmetic composition, characterized in that it contains a weight ratio of 1: 0.2 ~ 1: 10 of the extract of yeokpoe and yanggwi poppy. According to claim 1,
The mixed extract is a cosmetic composition, characterized in that contained 0.001 to 50% by weight relative to the total weight of the cosmetic composition. According to claim 1,
The cosmetic composition is a cosmetic composition, characterized in that for skin soothing, skin moisturizing, anti-inflammatory or anti-allergic. A pharmaceutical composition for skin soothing, comprising a mixed extract comprising a centella extract and a poppy extract as an active ingredient. A quasi-drug composition for skin soothing, containing a mixed extract comprising a centella extract and a poppy extract as an active ingredient.